These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 37821912)

  • 21. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease.
    Julayanont P; Brousseau M; Chertkow H; Phillips N; Nasreddine ZS
    J Am Geriatr Soc; 2014 Apr; 62(4):679-84. PubMed ID: 24635004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI).
    Crane PK; Carle A; Gibbons LE; Insel P; Mackin RS; Gross A; Jones RN; Mukherjee S; Curtis SM; Harvey D; Weiner M; Mungas D;
    Brain Imaging Behav; 2012 Dec; 6(4):502-16. PubMed ID: 22782295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy and Psychometric Properties of the Brazilian Version of the Montreal Cognitive Assessment as a Brief Screening Tool for Mild Cognitive Impairment and Alzheimer's Disease in the Initial Stages in the Elderly.
    Pinto TCC; Machado L; Costa MLG; Santos MSP; Bulgacov TM; Rolim APP; Silva GA; Rodrigues-Júnior AL; Sougey EB; Ximenes RCC
    Dement Geriatr Cogn Disord; 2019; 47(4-6):366-374. PubMed ID: 31466064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is the Montreal Cognitive Assessment (MoCA) screening superior to the Mini-Mental State Examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer's Disease (AD) in the elderly?
    Pinto TCC; Machado L; Bulgacov TM; Rodrigues-Júnior AL; Costa MLG; Ximenes RCC; Sougey EB
    Int Psychogeriatr; 2019 Apr; 31(4):491-504. PubMed ID: 30426911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the utility of everyday memory test and the Alzheimer's Disease Assessment Scale-Cognitive part for evaluation of mild cognitive impairment and very mild Alzheimer's disease.
    Adachi H; Shinagawa S; Komori K; Toyota Y; Mori T; Matsumoto T; Sonobe N; Kashibayashi T; Ishikawa T; Fukuhara R; Ikeda M
    Psychiatry Clin Neurosci; 2013 Apr; 67(3):148-53. PubMed ID: 23581865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI.
    Skinner J; Carvalho JO; Potter GG; Thames A; Zelinski E; Crane PK; Gibbons LE;
    Brain Imaging Behav; 2012 Dec; 6(4):489-501. PubMed ID: 22614326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A subtest analysis of the Montreal cognitive assessment (MoCA): which subtests can best discriminate between healthy controls, mild cognitive impairment and Alzheimer's disease?
    Cecato JF; Martinelli JE; Izbicki R; Yassuda MS; Aprahamian I
    Int Psychogeriatr; 2016 May; 28(5):825-32. PubMed ID: 26620850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease.
    Sano M; Raman R; Emond J; Thomas RG; Petersen R; Schneider LS; Aisen PS
    Alzheimer Dis Assoc Disord; 2011; 25(2):122-7. PubMed ID: 20921876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamics of brain structure and cognitive function in the Alzheimer's disease neuroimaging initiative.
    Song X; Mitnitski A; Zhang N; Chen W; Rockwood K;
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):71-8. PubMed ID: 23123510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
    Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
    J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.
    Faust-Socher A; Duff-Canning S; Grabovsky A; Armstrong MJ; Rothberg B; Eslinger PJ; Meaney CA; Schneider RB; Tang-Wai DF; Fox SH; Zadikoff C; Kennedy N; Chou KL; Persad C; Litvan I; Mast BT; Gerstenecker AT; Weintraub S; Reginold W; Marras C
    Dement Geriatr Cogn Disord; 2019; 47(4-6):187-197. PubMed ID: 31315127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
    Wessels AM; Dowsett SA; Sims JR
    J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials.
    Raghavan N; Samtani MN; Farnum M; Yang E; Novak G; Grundman M; Narayan V; DiBernardo A;
    Alzheimers Dement; 2013 Feb; 9(1 Suppl):S21-31. PubMed ID: 23127469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).
    Arevalo-Rodriguez I; Smailagic N; Roqué I Figuls M; Ciapponi A; Sanchez-Perez E; Giannakou A; Pedraza OL; Bonfill Cosp X; Cullum S
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010783. PubMed ID: 25740785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic performance of a combination of Mini-Mental State Examination and Clock Drawing Test in detecting Alzheimer's disease.
    Kato Y; Narumoto J; Matsuoka T; Okamura A; Koumi H; Kishikawa Y; Terashima S; Fukui K
    Neuropsychiatr Dis Treat; 2013; 9():581-6. PubMed ID: 23662057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Properties of odor identification testing in screening for early-stage Alzheimer's disease.
    Audronyte E; Pakulaite-Kazliene G; Sutnikiene V; Kaubrys G
    Sci Rep; 2023 Apr; 13(1):6075. PubMed ID: 37055436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Research on predicting the risk of mild cognitive impairment in the elderly based on the joint model].
    Xu J; Yuan MQ; Fang Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Feb; 43(2):269-276. PubMed ID: 35184495
    [No Abstract]   [Full Text] [Related]  

  • 38. A comparative study on the validations of three cognitive screening tests in identifying subtle cognitive decline.
    Pan FF; Huang L; Chen KL; Zhao QH; Guo QH
    BMC Neurol; 2020 Mar; 20(1):78. PubMed ID: 32138678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting Alzheimer's disease based on survival data and longitudinally measured performance on cognitive and functional scales.
    Wu Y; Zhang X; He Y; Cui J; Ge X; Han H; Luo Y; Liu L; Wang X; Yu H;
    Psychiatry Res; 2020 Sep; 291():113201. PubMed ID: 32559670
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.